Guangzhou's biopharmaceutical industry thrives with cutting-edge innovations

Guangzhou is home to over 6,500 biopharmaceutical companies, hosting 12 Fortune Global 500 firms, leading the nation in industry scale, company quantity, and innovation capability.

On March 25, the Human Cell Lineage Grand Scientific Research Facility was launched on Guangzhou International Bio Island, poised to unlock the mysteries of life and death.

Rendering of the Human Cell Lineage Grand Scientific Research Facility. [Photo/WeChat account: guangzhougaoxinqu]

Previously, Guangzhou's Akeso's bispecific antibody drug Ivonescimab outperformed international top-selling cancer drugs. Akeso's self-developed tumor bispecific antibody drug Cadonilimab achieved substantial sales in its first year on the market.

Despite massive research and development investments, BeiGene reshaped China's history of cancer drugs with zanubrutinib, yielding remarkable results. BeiGene's market value surpassed Jiangsu Hengrui Pharmaceuticals, claiming the throne of "China's Drug King".

Guangzhou's pharmaceutical companies, like Lupeng Pharmaceutical, are continuously innovating. Its core project, Rocbrutinib, the world's first fourth-generation Bruton's tyrosine kinase (BTK) covalent and non-covalent inhibitor, is currently one of the fastest-growing products globally.

Guangzhou may birth the next "Global Drug King" in the future.

Share - WeChat